ERBB2 and breast cancer: In a large meta-analysis, Kuksis et al., reported a brain metastases incidence in metastatic breast cancer of 31% for the HER2+ subgroup and 32% for the TNBC subgroup, compared to 15% among patients with the HR+/HER2− subtype; these findings highlight the high incidence of brain metastases among patients with HER2+ and TNBC breast cancer and suggest a screening program for these populations [28].